Alzheimer%s Disease Therapeutics and Diagnostics: Global Markets
- March 2016 •
- 144 pages •
- Report ID: 170505
Use this report to:
Define AD and discuss disease-related events, etiology and epidemiology of AD.
Investigate the global and regional markets for the drugs and diagnostic technologies for the treatment of Alzheimer’s disease (AD).
Analyze market dynamics for the interpretation and forecasting of the sales of AD drugs and diagnostics.
Evaluate the developments in the global market for AD therapeutics and diagnostics.
The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.
The North American market should reach over $2.9 billion by 2020 from 2.2 billion in 2015, at a CAGR of 5.3% from 2015 to 2020.
The Asia-Pacific market should reach over $2.6 billion by 2020 from $1.6 billion in 2015, at a CAGR of 10.7% from 2015 to 2020.
The aim of this report is to investigate the global and regional markets for the drugs and diagnostic technologies used for the treatment and diagnostic evaluation of Alzheimer’s disease (AD).
This report defines AD and discusses the disease-related events, etiology and epidemiology of AD by providing information on prevalence and incidence rates, diagnostic tools and equipment, and by introducing important scientific and technological frameworks to better grasp the developments in the global market for AD therapeutics and diagnostics.
Products that are currently available for the diagnosis and treatment of AD are introduced and evaluated according to the report’s methodology. The report also highlights promising new drug candidates and diagnostic imaging agents.
Key drivers and restraints, as well as major opportunities versus threats for the future growth and direction of the individual and global markets, are identified and addressed.
The classification and comparison of distinct segments of AD drugs and diagnostic imaging products are provided in the report, and current and future developments are highlighted for each existing and novel market segment.
Current market dynamics and characteristics are analyzed for the interpretation and forecasting of the sales of AD drugs and diagnostics. Product revenues are broken down by regional and country markets. Sales figures are estimated for the global and regional markets for the period between 2015 and 2020.
REASONS FOR DOING THE STUDY
Alzheimer’s disease cannot be prevented, cured or slowed, and it is a rapidly growing and serious health problem, affecting more than 17 million worldwide. Therapies for AD provide temporary and modest improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease progression. The mmense size of the affected population and lack of appropriate and effective treatment offers a tremendous commercial opportunity.
The understanding of the underlying reasons and mechanisms involved in AD is very limited. Drug developers have been failing to demonstrate meaningful clinical benefits of treatment for a myriad of investigational compounds due to stringent regulations.
High drug attrition rates and long drug approval times have driven pharmaceutical companies and technology ventures closer to each for collaboration. Specifically, diagnostic technology companies are rigorously trying to bring about effective biomarker technologies to assist and enhance the drug development process for prospective drug candidates. Regulatory bodies are highly supportive of the use of diagnostic technologies in order to improve drug attrition rates.
Despite the recurring failures in the development of novel therapies for AD, the global markets are demanding new and more effective, disease attenuating treatments, with first-in-class approvals. This expectation and the increasing incidence of AD associated with the aging population are driving the market.